Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. For decades, efforts to develop non-opioid pain drugs were marked by failure. Those given either dose of Latigo’s oral drug, LTG-001, showed statistically significant pain relief compared to placebo after 48 hours. And while participants in all groups had the option to use the opioid oxycodone if they needed additional pain management, those on a high dose of Latigo’s therapy were significantly less likely to do so than participants on placebo. AdvertisementThe drug was generally safe and well tolerated, with higher overall adverse event rates in the placebo group than in either treatment group.